FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesMedidata webinar - Evolution of Trial Virtualization & its Impact on Clinical Supplies
Topic: Supply Chain
Webinar
Free
EU Clinical Trial Regulation 536/2014
Topic: Regulatory
Position Paper
Members
Value-Based Healthcare
Topic: Health Care
Report
Members
